CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $84,839,893 | +110.4% | 2,852,720 | +27.5% | 0.01% | +150.0% |
| Q2 2023 | $40,323,985 | +13.2% | 2,237,735 | +0.9% | 0.00% | 0.0% |
| Q1 2023 | $35,633,832 | -51.4% | 2,218,794 | -44.7% | 0.00% | 0.0% |
| Q4 2022 | $73,375,094 | +106.6% | 4,009,568 | +121.7% | 0.00% | 0.0% |
| Q3 2022 | $35,522,000 | +8.2% | 1,808,665 | +2.7% | 0.00% | 0.0% |
| Q2 2022 | $32,840,000 | -12.0% | 1,760,845 | +3.5% | 0.00% | 0.0% |
| Q1 2022 | $37,330,000 | +1.0% | 1,700,679 | +30.8% | 0.00% | 0.0% |
| Q4 2021 | $36,944,000 | +57.3% | 1,300,374 | +16.5% | 0.00% | +100.0% |
| Q3 2021 | $23,489,000 | +128.0% | 1,115,859 | +104.2% | 0.00% | 0.0% |
| Q2 2021 | $10,300,000 | +42.6% | 546,432 | +15.6% | 0.00% | – |
| Q1 2021 | $7,221,000 | +6.4% | 472,561 | -1.7% | 0.00% | – |
| Q4 2020 | $6,784,000 | -2.4% | 480,799 | +8.3% | 0.00% | – |
| Q3 2020 | $6,954,000 | -5.3% | 443,775 | +5.9% | 0.00% | -100.0% |
| Q2 2020 | $7,340,000 | +122.4% | 418,975 | +86.6% | 0.00% | – |
| Q1 2020 | $3,300,000 | -42.0% | 224,494 | -0.9% | 0.00% | – |
| Q4 2019 | $5,685,000 | +83.2% | 226,601 | +9.8% | 0.00% | – |
| Q3 2019 | $3,103,000 | -39.0% | 206,296 | +1.3% | 0.00% | – |
| Q2 2019 | $5,091,000 | +112.2% | 203,628 | +93.2% | 0.00% | – |
| Q1 2019 | $2,399,000 | -22.4% | 105,399 | +2.2% | 0.00% | – |
| Q4 2018 | $3,093,000 | +41.3% | 103,148 | +35.0% | 0.00% | – |
| Q3 2018 | $2,189,000 | – | 76,379 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |